Ouro Medicines

Ouro Medicines is a clinical-stage biotechnology company based in South San Francisco, California, defining the future of treatment for people with immune-mediated diseases. Its pipeline centers on T cell engager programs for autoimmune conditions, including the lead candidate OM336 (evaluated in the AIC-1001 clinical trial), alongside an expanded access policy. The company was surfaced as a portfolio company of Norwest Venture Partners and added to the API Evangelist network as a lead. As a therapeutics developer, Ouro Medicines publishes a corporate and scientific website but no public developer program, API, or technical documentation surface. Recent company news includes a definitive agreement for Gilead Sciences to acquire Ouro Medicines to advance its first-in-class T cell engager program for autoimmune diseases.

Ouro Medicines is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immunology, and Immune-Mediated Diseases.

Ouro Medicines’ developer surface includes engineering blog and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalsImmunologyImmune-Mediated DiseasesAutoimmune DiseasesClinical TrialsLife SciencesTherapeutics

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.1/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ouromedicines: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Ouromedicines Domain Security

TLSv1.3

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: ouromedicines
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/ouromedicines.png
name: Ouro Medicines
description: Ouro Medicines is a clinical-stage biotechnology company based in South San Francisco, California, defining the
  future of treatment for people with immune-mediated diseases. Its pipeline centers on T cell engager programs for autoimmune
  conditions, including the lead candidate OM336 (evaluated in the AIC-1001 clinical trial), alongside an expanded access
  policy. The company was surfaced as a portfolio company of Norwest Venture Partners and added to the API Evangelist network
  as a lead. As a therapeutics developer, Ouro Medicines publishes a corporate and scientific website but no public developer
  program, API, or technical documentation surface. Recent company news includes a definitive agreement for Gilead Sciences
  to acquire Ouro Medicines to advance its first-in-class T cell engager program for autoimmune diseases.
url: https://raw.githubusercontent.com/api-evangelist/ouromedicines/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- norwest-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immunology
- Immune-Mediated Diseases
- Autoimmune Diseases
- Clinical Trials
- Life Sciences
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/ouromedicines-domain-security.yml
- type: Website
  url: https://ouromedicines.com
- type: Blog
  url: https://ouromedicines.com/news/
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1